PLUS THERAPEUTICS Regains Nasdaq Compliance After 1-for-25 Reverse Split

What Happened
PLUS THERAPEUTICS, Inc. (PSTV) announced via Form 8-K filed April 21, 2026 that Nasdaq sent a Notification Letter confirming the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq’s notice followed the Company’s one-for-twenty-five reverse split of its common stock, which became effective April 2, 2026. The Company also issued a press release on April 21, 2026 announcing receipt of the Notification Letter (Exhibit 99.1).

Key Details

• Reverse split: one-for-twenty-five (1-for-25) reverse split of common stock, effective April 2, 2026.
• Nasdaq rule: Regained compliance with Nasdaq Listing Rule 5550(a)(2) (minimum bid price requirement).
• Filing and announcement: Form 8-K filed April 21, 2026; press release attached as Exhibit 99.1.
• Authorized signature: Report signed by Marc H. Hedrick, M.D., President and CEO.

Why It Matters
Regaining compliance with Nasdaq’s minimum bid price rule removes a key threat of delisting and allows PLUS THERAPEUTICS to remain listed on the Nasdaq Capital Market, preserving market access and liquidity for shareholders. This action is procedural—resulting from the reverse stock split—and does not itself change the company’s business fundamentals or financial results. Investors should note the compliance update but continue to review the company’s operational and financial disclosures for fundamental performance.